Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: A quantitative and qualitative study

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 2, 2014, Pages 160-167

  Sanchez Padilla, Elisabeth ^a   Marquer, C ^a   Kalon, S ^b   Qayyum, S ^b   Hayrapetyan, A ^c   Varaine, F ^b   Bastard, M ^a   Bonnet, M ^a  

^a EPICENTRE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c National Tuberculosis   (Armenia)

Author keywords

Default; Resistance; Tuberculosis

Indexed keywords

CAPREOMYCIN; KANAMYCIN;

ADULT; ARMENIA; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG RESISTANT TUBERCULOSIS; ECONOMIC EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RETROSPECTIVE STUDY; THERAPY DELAY; THERAPY RESISTANCE; TREATMENT DEFAULT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; ANTITUBERCULAR AGENTS; ARMENIA; DRUG RESISTANCE, BACTERIAL; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT DROPOUTS; PERCEPTION; QUALITATIVE RESEARCH; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84892619237     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0369     Document Type: Article

References (38)

1. World Health Organization. Global tuberculosis control. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
2. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB). 2010 Global report on surveillance and response. Geneva, Switzerland: WHO, 2010.
3. World Health Organization. Global tuberculosis control. WHO/ HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010.
4. Migliori G B, D'Arcy R M, Sotgiu G, Lange C. Multidrugr esistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control. Clin Chest Med 2009; 30: 637-665, 7.
5. World Health Organization Europe. Tuberculosis assessment mission to Armenia. EUR/05/505051892. Copenhagen, Denmark: WHO, 2005.
6. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
7. Laserson K F, Thorpe L E, Leimane V, et al. Speaking the same language: treatment outcome Definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
8. Cox H S, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLOS ONE 2007; 2: e1126.
9. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
10. Shean K P, Willcox P A, Siwendu S N, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12: 1182-1189.
11. Holtz T H, Lancaster J, Laserson K F, Wells C D, Thorpe L, Weyer K. Risk factors associated with default from multidrugresistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006; 10: 649-655.
12. Gler M T, Podewils L J, Munez N, Galipot M, Quelapio M I D, Tupasi T E. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. Int J T uberc Lung Dis 2012; 16: 955-960.
13. Franke M F, Appleton S C, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008; 46: 1844-1851.
14. Gelmanova I Y, Keshavjee S, Golubchikova V T, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007; 85: 703-711.
15. Culqui D R, Munayco E C V, Grijalva C G, et al. Factors a ssociated with the non-completion of conventional antit uberculosis treatment in Peru. Arch Bronconeumol 2012; 48: 150-155.
16. Tekle B, Mariam D H, Ali A. Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia. Int J Tuberc Lung Dis 2002; 6: 573-579.
17. Protopopescu C, Raffi F, Roux P, et al. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother 2009; 64: 599-606.
18. Mills E J, Nachega J B, Bangsberg D R, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLOS Med 2006; 3: e438.
19. Catz S L, Kelly J A, Bogart L M, Benotsch E G, McAuliffe T L. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000; 19: 124-133.
20. Wasti S P, van Teijlingen E, Simkhada P, et al. Factors infl uencing adherence to antiretroviral treatment in Asian developing countries: a systematic review. Trop Med Int Health 2012; 17: 71-81.
21. Törün T, Güngör G, Özmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-1377.
22. Sagwa E, Mantel-Teeuwisse A K, Ruswa N, et al. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. South Med Rev 2012; 5: 6-13.
23. Bloss E, Kukša L, Holtz T H, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010; 14: 275-281.
24. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 299-307.
25. Brust J C M, Gandhi N R, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 2010; 14: 413-419.
26. Dooley K E, Lahlou O, Ghali I, et al. Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. BMC Public Health 2011; 11: 140.
27. Jha U M, Satyanarayana S, Dewan P K, et al. Risk factors for treatment default among re-treatment tuberculosis patients in India, 2006. PLOS ONE 2010; 5: e8873.
28. Muture B N, Keraka M N, Kimuu P K, Kabiru E W, Ombeka V O, Oguya F. Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study. BMC Public Health 2011; 11: 696.
29. Minasyan A, Poghosyan A, Hakobyan T, Hanchilova B. Work migration from Armenia. Household survey 2005-2007. Yerevan, Armenia: Advanced Social Technologies, Organization for Security and Co-operation in Europe, 2007.
30. Somach S. The other side of the gender equation: gender issues for men in the Europe and Eurasia Region. Washington DC, USA: United States Agency for International Development, 2011.
31. Santha T, Garg R, Frieden T R, et al. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000. Int J Tuberc Lung Dis 2002; 6: 780-788.
32. Fry R S, Khoshnood K, Vdovichenko E, et al. Barriers to completion of tuberculosis treatment among prisoners and former prisoners in St Petersburg, Russia. Int J Tuberc Lung Dis 2005; 9: 1027-1033.
33. Alexy E R, Podewils L J, Mitnick C D, Becerra M C, Laserson K F, Bonilla C. Concordance of programmatic and laboratorybased multidrug-resistant tuberculosis treatment outcomes in Peru. Int J Tuberc Lung Dis 2012; 16: 364-369.
34. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision. WHO/HTM/TB/2013.2. Geneva, Switzerland: WHO, 2013.
35. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
36. Diacon A H, Dawson R, von Groote-Bidlingmaier F, et al. 14- day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifl oxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
37. Diacon A H, Donald P R, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug- resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276.
38. Gler M T, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.